ALNY Alnylam Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY

Price (delayed)

$189.98

Market cap

$23.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.3

Enterprise value

$24.04B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The company's revenue rose by 23% YoY and by 8% QoQ
The gross profit is up by 23% YoY and by 8% from the previous quarter
The company's net income fell by 33% YoY but it rose by 4.3% QoQ
ALNY's EPS is down by 29% year-on-year but it is up by 4.8% since the previous quarter
The equity has plunged by 134% from the previous quarter and by 127% YoY
The debt has grown by 32% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.alnylam.com/
Peers: ARWR REGN SRPT OPK

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
124.13M
Market cap
$23.58B
Enterprise value
$24.04B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
22.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.17
Earnings
Revenue
$1.04B
EBIT
-$971.03M
EBITDA
-$885.48M
Free cash flow
-$613.33M
Per share
EPS
-$9.3
Free cash flow per share
-$5.04
Book value per share
-$1.29
Revenue per share
$8.53
TBVPS
$29.14
Balance sheet
Total assets
$3.55B
Total liabilities
$3.7B
Debt
$1.32B
Equity
-$158.22M
Working capital
$1.92B
Liquidity
Debt to equity
-8.34
Current ratio
3.51
Quick ratio
3.16
Net debt/EBITDA
-0.51
Margins
EBITDA margin
-85.4%
Gross margin
83.7%
Net margin
-109%
Operating margin
-75.7%
Efficiency
Return on assets
-32.7%
Return on equity
-1,287.8%
Return on invested capital
-30.8%
Return on capital employed
-34.9%
Return on sales
-93.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-0.27%
1 week
2.44%
1 month
0.11%
1 year
16.05%
YTD
-20.06%
QTD
-20.06%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$868.6M
Operating income
-$785.07M
Net income
-$1.13B
Gross margin
83.7%
Net margin
-109%
The company's net income fell by 33% YoY but it rose by 4.3% QoQ
The company's revenue rose by 23% YoY and by 8% QoQ
The gross profit is up by 23% YoY and by 8% from the previous quarter
The net margin has grown by 11% from the previous quarter but it has contracted by 8% YoY

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
22.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.17
ALNY's EPS is down by 29% year-on-year but it is up by 4.8% since the previous quarter
The equity has plunged by 134% from the previous quarter and by 127% YoY
ALNY's price to sales (P/S) is 59% lower than its 5-year quarterly average of 54.4 and 7% lower than its last 4 quarters average of 23.9
The company's revenue rose by 23% YoY and by 8% QoQ

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
The ROE has plunged by 199% from the previous quarter
The return on assets has declined by 33% year-on-year but it has increased by 3.5% since the previous quarter
ALNY's return on invested capital is down by 25% year-on-year but it is up by 5% since the previous quarter
ALNY's return on sales is up by 12% since the previous quarter but it is down by 11% year-on-year

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 4.3% less than the total liabilities
The company's total liabilities rose by 21% YoY and by 2.8% QoQ
The company's quick ratio fell by 17% YoY
The equity has plunged by 134% from the previous quarter and by 127% YoY
Alnylam Pharmaceuticals's debt to equity has soared by 57% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.